91 related articles for article (PubMed ID: 8859942)
1. Hemodynamic characterization of a novel neuropeptide Y receptor antagonist.
Tadepalli AS; Harrington WW; Hashim MA; Matthews J; Leban JJ; Spaltenstein A; Daniels AJ
J Cardiovasc Pharmacol; 1996 May; 27(5):712-8. PubMed ID: 8859942
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
[TBL] [Abstract][Full Text] [Related]
3. Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed ovariectomized rats may involve neuropeptide Y Y1 and Y4 receptors.
Jain MR; Pu S; Kalra PS; Kalra SP
Endocrinology; 1999 Nov; 140(11):5171-7. PubMed ID: 10537146
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascular postsynaptic receptors.
Lew MJ; Murphy R; Angus JA
Br J Pharmacol; 1996 Apr; 117(8):1768-72. PubMed ID: 8732289
[TBL] [Abstract][Full Text] [Related]
5. Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat?
Zhao XH; Sun XY; Edvinsson L; Hedner T
J Hypertens; 1997 Jan; 15(1):19-27. PubMed ID: 9050966
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of the gonadotropic axis by the neuropeptide Y receptor Y1 antagonist/Y4 agonist 1229U91 in the male rat.
Raposinho PD; Broqua P; Hayward A; Akinsanya K; Galyean R; Schteingart C; Junien J; Aubert ML
Neuroendocrinology; 2000 Jan; 71(1):2-7. PubMed ID: 10644893
[TBL] [Abstract][Full Text] [Related]
7. Potent neuropeptide Y Y1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake.
Kanatani A; Ishihara A; Asahi S; Tanaka T; Ozaki S; Ihara M
Endocrinology; 1996 Aug; 137(8):3177-82. PubMed ID: 8754736
[TBL] [Abstract][Full Text] [Related]
8. Effects of intracerebroventricular administration of the NPY-Y1 receptor antagonist, 1229U91, on hyperphagic and glycemic responses to acute and chronic intermediate insulin-induced hypoglycemia in female rats.
Nedungadi TP; Briski KP
Regul Pept; 2010 Jan; 159(1-3):14-8. PubMed ID: 19616044
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y Y1 receptor antagonist (BIBP 3226) attenuates stress evoked tachycardia in conscious spontaneously hypertensive rats.
Zhang W; Lundberg JM; Thorén P
Cardiovasc Drugs Ther; 1997 Dec; 11(6):801-6. PubMed ID: 9512876
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
[TBL] [Abstract][Full Text] [Related]
11. Age-dependent hyperresponsiveness of spontaneously hypertensive rats to the pressor effects of intravenous neuropeptide Y (NPY): role of mode of peptide administration and plasma NPY-like immunoreactivity.
Miller DW; Tessel RE
J Cardiovasc Pharmacol; 1991 Nov; 18(5):647-56. PubMed ID: 1723760
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptides in hypertension: role of neuropeptide Y and calcitonin gene related peptide.
Westfall TC; Han SP; Knuepfer M; Martin J; Chen XL; del Valle K; Ciarleglio A; Naes L
Br J Clin Pharmacol; 1990; 30 Suppl 1(Suppl 1):75S-82S. PubMed ID: 2268510
[TBL] [Abstract][Full Text] [Related]
13. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats.
Vonend O; Okonek A; Stegbauer J; Habbel S; Quack I; Rump LC
Cardiovasc Res; 2005 May; 66(2):345-52. PubMed ID: 15820203
[TBL] [Abstract][Full Text] [Related]
14. Increased vasopressor actions of intraventricular neuropeptide Y-(13-36) in spontaneously hypertensive versus normotensive Wistar-Kyoto rats. Possible relationship to increases in Y2 receptor binding in the nucleus tractus solitarius.
Aguirre JA; Hedlund PB; Narváez JA; Bunnemann B; Ganten D; Fuxe K
Brain Res; 1995 Jul; 684(2):159-64. PubMed ID: 7583217
[TBL] [Abstract][Full Text] [Related]
15. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
Iyengar S; Li DL; Simmons RM
J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
[TBL] [Abstract][Full Text] [Related]
16. Hypothalamic NPY status during positive energy balance and the effects of the NPY antagonist, BW 1229U91, on the consumption of highly palatable energy-rich diet.
Widdowson PS; Henderson L; Pickavance L; Buckingham R; Tadayyon M; Arch JR; Williams G
Peptides; 1999; 20(3):367-72. PubMed ID: 10447095
[TBL] [Abstract][Full Text] [Related]
17. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension.
Douglas SA; Gellai M; Ezekiel M; Ohlstein EH
J Hypertens; 1994 May; 12(5):561-7. PubMed ID: 7930556
[TBL] [Abstract][Full Text] [Related]
18. Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors.
Kannoa T; Kanatani A; Keen SL; Arai-Otsuki S; Haga Y; Iwama T; Ishihara A; Sakuraba A; Iwaasa H; Hirose M; Morishima H; Fukami T; Ihara M
Peptides; 2001 Mar; 22(3):405-13. PubMed ID: 11287095
[TBL] [Abstract][Full Text] [Related]
19. Effects of neuropeptide Y and [Leu31,Pro34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat.
Penner SB; Smyth DD; Glavin GB
J Pharmacol Exp Ther; 1993 Jul; 266(1):339-43. PubMed ID: 8101219
[TBL] [Abstract][Full Text] [Related]
20. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
